Home-based fecal calprotectin test is expected to play an important role in patients with inflammatory bowel diseases

Content Provider	Semantic Scholar
Author	Kim, Young-Ho
Copyright Year	2018
Abstract	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. However, the main hurdle for using FC as a biomarker to monitor disease activity is patient reluctance to collect and bring samples to the hospital. In this regard, the research of Wei et al. is very important and timely. They prospectively enrolled consecutive patients with IBD in clinical remission and assess ed FC by using both laboratory and home-based tests. The correlation between the laboratory and home-based tests was good and most patients found the home-based test to be feasible and easy to use and preferred it over the laboratory test. Home-based tests can overcome the reluctance to use fecal tests. In addition, home-based FC tests can be conducted when patient symptoms deteriorate between outpatient visits, and physicians can use FC test results between outpatient visits and at an outpatient visit to establish the therapeutic plan. Moreover, results of home-based FC tests can be reported to physicians on the internet. Using the results, physicians can predict a relapse and undertake immediate action. This approach would enable telemedicine. However, there are several issues to consider in using homebased FC tests in actual practice. As the authors pointed out, the patients enrolled in this study had an active desire to use the test, which caused them to overestimate the feasibility and satisfaction with the home-based test. For example, one study showed a significant difference in correlation coefficients Home-based fecal calprotectin test is expected to play an important role in patients with inflammatory bowel diseases
Starting Page	507
Ending Page	508
Page Count	2
File Format	PDF HTM / HTML
Alternate Webpage(s)	https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fe/e0/ir-2018-00136.PMC6223454.pdf
PubMed reference number	30369230
Alternate Webpage(s)	https://doi.org/10.5217/ir.2018.00136
DOI	10.5217/ir.2018.00136
Journal	Intestinal research
Volume Number	16
Language	English
Access Restriction	Open
Subject Keyword	Biological Markers Fecal Incontinence Inflammatory Bowel Diseases Intestinal Diseases Intestines Irritable Bowel Syndrome Laboratory Procedures License Patient Visit Patients Reluctance Telemedicine
Content Type	Text
Resource Type	Article